Michael Pellini, M.D.
Managing Partner, Section 32
Mike Pellini is a managing partner of Section 32, a venture fund that invests in companies and inventors that are changing the way technology betters humanity.
Mike holds a B.A. from Boston College, an MBA from Drexel University and an M.D. from Jefferson Medical College.
Previously, he served as CEO of Foundation Medicine from 2011 until he transitioned to chairman in 2017. He currently serves as a member of the board of directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies, Octave BioSciences, Cradle Genomics, the Personalized Cancer Coalition and the Mission Hospital Foundation.
As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Mike brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. He is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the advisory board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health).
Back to Who We Are